II.e

Transfusion-related acute lung injury (TRALI or -ARDS)

(Fr: OAP transfusionnel. A distinguer de l'OAP de surcharge). TRALI is a distinctive form of ARDS or NCPE (see under IIa, IIb) due to transfusion/infusion of allogeneic blood, platelets, stem-/marrow cells, IVIG or FFP. Typically, TRALI develops within 6-8h of transfusion. Examination of each donor in the pool (more often a multiparous woman) for the presence of pathogenic antibodies to a cognate Ab in the recipient is indicated to prevent further TRALI in other recipents, and the bloodbank shoulb be notified. The syndrome is underappreciated and is amenable to risk reduction strategies (e.g. men-only donor poliicy, Ab screening). TRALI (PMID 25611652) must me differentiated from TACO (Transfusion Associated Circulatory Overload: PMID 17898575, 24360126, 25611653). Predisposing risk factos may account for posttransfusion ARDS also known as 'possible TRALI' (PMID 25488517).

Last update : 17/04/2017
 

Causative drugs

8

Hemotherapy (transfusion/infusion of whole blood, red cells, platelets, or blood products)

I.l I - Interstitial/parenchymal lung disease
I.l - Diffuse alveolar damage (DAD) (see alsoo under IIb and XVf)
I.y I - Interstitial/parenchymal lung disease
I.y - Progression, acceleration or exacerbation of preexisting ILD/fibrosis
II.a II - Pulmonary edema - ARDS - Acute respiratory failure
II.a - Pulmonary edema, noncardiogenic (NCPE)
II.b II - Pulmonary edema - ARDS - Acute respiratory failure
II.b - ARDS
II.e II - Pulmonary edema - ARDS - Acute respiratory failure
II.e - Transfusion-related acute lung injury (TRALI or -ARDS)
II.f II - Pulmonary edema - ARDS - Acute respiratory failure
II.f - Hypoxemia, low saturation (may occur in isolation)
II.h II - Pulmonary edema - ARDS - Acute respiratory failure
II.h - Overload pulmonary edema (including TACO)
III.a III - Pulmonary hemorrhage
III.a - Diffuse alveolar hemorrhage (DAH)
VI.a VI - Pulmonary vasculopathy
VI.a - Pulmonary embolism - Venous thromboembolism
VI.i VI - Pulmonary vasculopathy
VI.i - Acute pulmonary hypertension
VI.n VI - Pulmonary vasculopathy
VI.n - Crystal pulmonary embolism
VIII.a VIII - Upper, central, large airway involvement
VIII.a - Angioedema (may cause UAO & asphyxia)
X.f X - Systemic conditions, syndromes and reactions
X.f - Anaphylaxis
XI.d XI - Miscellaneous
XI.d - Metabolic acidosis (incl. lactic-). May cause dyspnea
XI.n XI - Miscellaneous
XI.n - Neutropenia, agranulocytosis (w/wo infection/sepsis)
XII.j XII - Cardiovascular involvement / toxicity
XII.j - Myocardial stunning
XII.n XII - Cardiovascular involvement / toxicity
XII.n - Hypotension, shock, cardiovascular collapse
XV.g XV - Pulmonary pathology
XV.g - Path: Alveolar hemorrhage (see also IIIa)
XV.w XV - Pulmonary pathology
XV.w - Path: Pulmonary edema (see also II/IIa)
XV.aj XV - Pulmonary pathology
XV.aj - Path: Cholesterol crystal embolism
XV.at XV - Pulmonary pathology
XV.at - Path: Pulmonary capillary granulocyte sequestration
XVI.d XVI - Imaging
XVI.d - Imaging: Alveolar opacities with a batwing or butterfly distribution
XVII.ad XVII - Infections & related conditions
XVII.ad - Systemic infection (transmitted)
5

Status post-hematopoietic stem cell (HSCT) or bone marrow transplantation (BMT)

I.b I - Interstitial/parenchymal lung disease
I.b - Pneumonitis (ILD)
I.d I - Interstitial/parenchymal lung disease
I.d - Organizing pneumonia (A pattern consistent with)
I.f I - Interstitial/parenchymal lung disease
I.f - Acute fibrinous organizing pneumonia (AFOP)
I.g I - Interstitial/parenchymal lung disease
I.g - Pulmonary fibrosis
I.n I - Interstitial/parenchymal lung disease
I.n - Pulmonary alveolar proteinosis (PAP)
I.v I - Interstitial/parenchymal lung disease
I.v - Subclinical changes in lung function/PFT
I.x I - Interstitial/parenchymal lung disease
I.x - Pleuroparenchymal fibroelastosis (PPFE)
II.a II - Pulmonary edema - ARDS - Acute respiratory failure
II.a - Pulmonary edema, noncardiogenic (NCPE)
II.e II - Pulmonary edema - ARDS - Acute respiratory failure
II.e - Transfusion-related acute lung injury (TRALI or -ARDS)
II.n II - Pulmonary edema - ARDS - Acute respiratory failure
II.n - Engraftment syndrome
III.a III - Pulmonary hemorrhage
III.a - Diffuse alveolar hemorrhage (DAH)
IV.c IV - Airway involvement
IV.c - Obliterative bronchiolitis (see also IVn)
V.f V - Pleural and/or pericardial involvement
V.f - Pneumothorax
VI.b VI - Pulmonary vasculopathy
VI.b - Pulmonary arterial hypertension
X.c X - Systemic conditions, syndromes and reactions
X.c - Capillary/vascular leak syndrome (CLS) (see also under Xr)
XII.a XII - Cardiovascular involvement / toxicity
XII.a - Left ventricular dysfunction/failure
XV.a XV - Pulmonary pathology
XV.a - Path: Cellular NSIP pattern (see also Ia, Ib)
XV.d XV - Pulmonary pathology
XV.d - Path: Acute fibrinous organizing pneumonia (AFOP-pattern) (see also If)
XV.f XV - Pulmonary pathology
XV.f - Path: Diffuse alveolar damage (DAD-pattern) (see also IL)
XV.g XV - Pulmonary pathology
XV.g - Path: Alveolar hemorrhage (see also IIIa)
XV.ak XV - Pulmonary pathology
XV.ak - Path: Pulmonary veno-occlusive disease (PVOD)
XV.ap XV - Pulmonary pathology
XV.ap - Path: Pleuroparenchymal fibrosis/fibroelastosis (PPFE)
XV.bv XV - Pulmonary pathology
XV.bv - Path: pulmonary cytolytic thrombi
XVII.m XVII - Infections & related conditions
XVII.m - Fungal airway infection
2